排卵誘発剤の世界市場レポート 2025年

排卵誘発剤市場規模は、今後数年間で力強い成長が見込まれます。2029年にはCAGR6.6％で61億2,000万米ドルに成長します。予測期間の成長は、ライフスタイルの変化と出産の遅れ、デジタルヘルスの統合、市場範囲の拡大、不妊率の上昇、カスタマイズされた治療レジメンなどに起因すると考えられます。予測期間の主な動向には、個別化治療アプローチ、生殖内分泌学の進歩、非侵襲的妊孕性モニタリング、生殖補助医療技術の需要増加、新規薬剤製剤の開発などがあります。

女性における不妊症の有病率の上昇は、排卵誘発剤市場の成長を促進すると予想されます。女性の不妊症は、避妊をしない性交渉を長期間（通常は1年以上）定期的に行っても妊娠しない、あるいは妊娠しても妊娠成立に至らない生物学的状態と定義されます。排卵誘発剤は、排卵不順または排卵の欠如に関連する問題に対処することによって、女性の不妊症を治療するために使用されます。これらの薬剤は、排卵プロセスに関与するホルモン経路を標的とし、成熟した卵子を放出するように卵巣を刺激します。例えば、米国の政府機関である疾病対策予防センターによると、2022年には、米国の15歳から44歳の女性約610万人が妊娠の課題に直面しており、これは全女性の約10％に相当します。さらに、米国の医療管理会社CCRM Management Company LLCが2022年6月に報告したように、不妊症は世界平均で4組に1組のカップルに影響を与え、毎年5％から10％増加しています。このように、女性の不妊症の有病率の増加が排卵誘発剤市場の成長を後押ししています。

体外受精（IVF）を選択する患者の増加は、今後数年間の排卵誘発剤市場の成長を促進すると予想されます。体外受精は、不妊の問題を抱える個人やカップルの妊娠を支援するために考案された複雑な一連の手順です。体外受精のプロトコールでは、排卵誘発剤を利用して卵巣を刺激し、採卵のために複数の卵子を産生させる。これらの薬剤は体外受精のプロセスに不可欠であり、成功の可能性を高める。例えば、2024年4月、米国を拠点とする医師や実験科学者を代表する組織である生殖補助医療学会は、卵子凍結サイクルの大幅な増加を報告し、前年の24,560から2022年には29,803に増加しました。その結果、体外受精を選択する患者の増加が排卵誘発剤市場の拡大に拍車をかけています。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場- 金利、インフレ、地政学、コロナ、回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界排卵誘発剤PESTEL分析（政治、社会、技術、環境、法的要因、促進要因、抑制要因）
• 最終用途産業の分析
• 世界の排卵誘発剤市場：成長率分析
• 世界の排卵誘発剤市場の実績：規模と成長, 2019-2024
• 世界の排卵誘発剤市場の予測：規模と成長, 2024-2029, 2034F
• 世界排卵誘発剤総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界の排卵誘発剤市場薬剤クラス別、実績と予測, 2019-2024, 2024-2029F, 2034F
• ホルモン
• 治療薬
• 世界の排卵誘発剤市場：投与経路別、実績と予測, 2019-2024, 2024-2029F, 2034F
• オーラル
• 非経口
• その他の投与経路
• 世界の排卵誘発剤市場：エンドユーザー別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院
• ホームケア
• 専門クリニック
• その他のエンドユーザー
• 世界の排卵誘発剤市場、ホルモンのサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• ゴナドトロピン
• クロミフェンクエン酸塩
• アロマターゼ阻害剤
• 世界の排卵誘発剤市場治療薬の種類別の細分化、実績と予測, 2019-2024, 2024-2029F, 2034F
• メトホルミン
• レトロゾール
• ブロモクリプチン

第7章 地域別・国別分析

• 世界の排卵誘発剤市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界の排卵誘発剤市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 排卵誘発剤市場：競合情勢
• 排卵誘発剤市場：企業プロファイル
  • Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Johnson And Johnson Pvt Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • Merck And Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Abbvie Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Novartis AG Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Bayer AG
• Sanofi SA
• Abbott Laboratories
• Gilead Sciences Inc.
• Amgen Inc.
• Teva Pharmaceutical Industries Ltd.
• Janssen Pharmaceutical Inc.
• Mylan N.V
• Astellas Pharma Inc.
• Sun Pharmaceuticals Industries Ltd.
• Aurobindo Pharma Limited
• Dr Reddy's Laboratories Ltd.
• Intas Pharmaceuticals Limited
• Endo International Inc.
• Ferring Pharmaceuticals Inc.

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• 排卵誘発剤市場2029：新たな機会を提供する国
• 排卵誘発剤市場2029：新たな機会を提供するセグメント
• 排卵誘発剤市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Ovulation-inducing drugs are medications used to stimulate the ovaries and facilitate the release of mature eggs (ovulation) in women facing challenges with their menstrual cycles or struggling with infertility. These drugs exert their effects on the hormonal balance in the body, specifically targeting the hormones involved in the ovulation process.

The primary types of ovulation-inducing drugs include hormones and therapeutic drugs. Hormone drugs are medications designed to modify or mimic the effects of naturally occurring hormones in the body. They can be administered through oral, topical, and other routes and are utilized by various end-users, including hospitals, homecare, specialty clinics, and others.

The ovulation-inducing drug market research report is one of a series of new reports from The Business Research Company that provides ovulation-inducing drug market statistics, including ovulation-inducing drug industry global market size, regional shares, competitors with a ovulation-inducing drug market share, detailed ovulation-inducing drug market segments, market trends and opportunities, and any further data you may need to thrive in the ovulation-inducing drug industry. This ovulation-inducing drug market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The ovulation inducing drugs market size has grown strongly in recent years. It will grow from $4.42 billion in 2024 to $4.74 billion in 2025 at a compound annual growth rate (CAGR) of 7.3%. The growth in the historic period can be attributed to development of clomiphene citrate, introduction of letrozole, regulatory approvals and standardization, emergence of ovulation predictor kits.

The ovulation inducing drugs market size is expected to see strong growth in the next few years. It will grow to $6.12 billion in 2029 at a compound annual growth rate (CAGR) of 6.6%. The growth in the forecast period can be attributed to changing lifestyles and delayed childbearing, digital health integration, expanding market reach, rising infertility rates, customized treatment regimens. Major trends in the forecast period include personalized treatment approaches, advancements in reproductive endocrinology, non-invasive fertility monitoring, rising demand for assisted reproductive technologies, development of novel drug formulations.

The rising prevalence of infertility among women is expected to drive the growth of the ovulation-inducing drug market. Women's infertility is defined as the biological condition where a woman is unable to conceive or carry a pregnancy to term after engaging in regular, unprotected sexual intercourse for an extended period, typically a year or more. Ovulation-inducing drugs are utilized to treat infertility in women by addressing issues related to irregular or absent ovulation. These medications target the hormonal pathways involved in the ovulation process, stimulating the ovaries to release mature eggs. For instance, according to the Centers for Disease Control and Prevention, a US government agency, in 2022, approximately 6.1 million women aged 15 to 44 in the US faced challenges in becoming pregnant, representing about 10% of all women. Additionally, as reported in June 2022 by CCRM Management Company LLC, a US-based medical management firm, infertility impacts 1 in 4 couples globally on average, with an annual increase of 5% to 10%. Thus, the growing prevalence of women's infertility is propelling the growth of the ovulation-inducing drug market.

The increasing number of patients choosing in vitro fertilization (IVF) is anticipated to drive the growth of the ovulation-inducing drugs market in the coming years. IVF is a complex set of procedures designed to assist individuals and couples experiencing fertility issues in achieving pregnancy. The IVF protocols utilize ovulation-inducing drugs to stimulate the ovaries, leading to the production of multiple eggs for retrieval. These medications are integral to the IVF process, enhancing the likelihood of successful outcomes. For example, in April 2024, The Society for Assisted Reproductive Technology, a US-based organization representing doctors and laboratory scientists, reported a significant rise in egg-freezing cycles, which increased from 24,560 the previous year to 29,803 in 2022. Consequently, the growing number of patients opting for IVF is fueling the expansion of the ovulation-inducing drugs market.

Major companies in the ovulation-inducing drugs market are proactively developing innovative drugs such as Cetrorelix acetate to secure approvals for treating women undergoing controlled ovarian stimulation. Cetrorelix acetate for injection, a gonadotropin-releasing hormone (GnRH) antagonist, has gained FDA approval, demonstrating its efficacy in preventing premature ovulation in women undergoing in vitro fertilization (IVF). In August 2022, Akorn Operating Company LLC received FDA approval for a generic version of cetrorelix acetate for injection, marking a significant advancement in fertility treatment. This development is aligned with the ongoing efforts of pharmaceutical companies, such as Akorn, to address infertility through innovative drugs.

In February 2024, Novo Holdings, a Denmark-based life sciences company, acquired Catalent Inc. for $16.5 billion. This acquisition is intended to bolster Novo Holdings' presence in the life sciences sector by utilizing Catalent's advanced capabilities in drug development, manufacturing, and delivery. The aim is to enhance innovation, streamline drug development processes, and broaden its global healthcare reach, particularly in high-demand areas such as biologics, gene therapies, and specialized drug delivery technologies. Catalent Inc., based in the US, provides a range of pharmaceuticals, including ovulation-inducing drugs.

Major companies operating in the ovulation inducing drugs market report are Pfizer Inc., Johnson And Johnson Pvt Ltd., Merck And Co. Inc., Abbvie Inc., Novartis AG, Bayer AG, Sanofi SA, Abbott Laboratories, Gilead Sciences Inc., Amgen Inc., Teva Pharmaceutical Industries Ltd., Janssen Pharmaceutical Inc., Mylan N.V, Astellas Pharma Inc., Sun Pharmaceuticals Industries Ltd., Aurobindo Pharma Limited, Dr Reddy's Laboratories Ltd., Intas Pharmaceuticals Limited, Endo International Inc., Ferring Pharmaceuticals Inc., Lupin Limited, LIVZON Pharmaceutical Group Inc., Torrent Pharmaceuticals Ltd., Gedeon Richter PLC, Glenmark Pharmaceuticals Ltd., Fresenius Kabi AG, Zydus Pharmaceuticals (USA) Inc., Serum Institute of India Ltd., EMD Serono Inc., Cipla Inc.

North America was the largest region in the ovulation-inducing drugs market in 2024. The regions covered in the ovulation inducing drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the ovulation inducing drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain

The ovulation-inducing drugs market consists of sales of clomiphene citrate (Clomid), letrozole (Femara), gonadotropins, human chorionic gonadotropin (hCG), bromocriptine (Cycloset, Parlodel). Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Ovulation Inducing Drugs Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on ovulation inducing drugs market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for ovulation inducing drugs ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The ovulation inducing drugs market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Drug Class: Hormones; Therapeutics Drugs
• 2) By Route Of Administration: Oral; Parenteral; Other Routes Of Administration
• 3) By End-User: Hospital; Homecare; Specialty Clinics; Other End-Users
• Subsegments:
• 1) By Hormones: Gonadotropins; Clomiphene Citrate; Aromatase Inhibitors
• 2) By Therapeutic Drugs: Metformin; Letrozole; Bromocriptine
• Companies Mentioned: Pfizer Inc.; Johnson And Johnson Pvt Ltd.; Merck And Co. Inc.; Abbvie Inc.; Novartis AG
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Ovulation Inducing Drugs Market Characteristics

3. Ovulation Inducing Drugs Market Trends And Strategies

4. Ovulation Inducing Drugs Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Covid And Recovery On The Market

5. Global Ovulation Inducing Drugs Growth Analysis And Strategic Analysis Framework

• 5.1. Global Ovulation Inducing Drugs PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Ovulation Inducing Drugs Market Growth Rate Analysis
• 5.4. Global Ovulation Inducing Drugs Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Ovulation Inducing Drugs Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Ovulation Inducing Drugs Total Addressable Market (TAM)

6. Ovulation Inducing Drugs Market Segmentation

• 6.1. Global Ovulation Inducing Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hormones
• Therapeutics Drugs
• 6.2. Global Ovulation Inducing Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Oral
• Parenteral
• Other Routes Of Administration
• 6.3. Global Ovulation Inducing Drugs Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals
• Homecare
• Specialty Clinics
• Other End-Users
• 6.4. Global Ovulation Inducing Drugs Market, Sub-Segmentation Of Hormones, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Gonadotropins
• Clomiphene Citrate
• Aromatase Inhibitors
• 6.5. Global Ovulation Inducing Drugs Market, Sub-Segmentation Of Therapeutic Drugs, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Metformin
• Letrozole
• Bromocriptine

7. Ovulation Inducing Drugs Market Regional And Country Analysis

• 7.1. Global Ovulation Inducing Drugs Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Ovulation Inducing Drugs Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Ovulation Inducing Drugs Market

• 8.1. Asia-Pacific Ovulation Inducing Drugs Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Ovulation Inducing Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Ovulation Inducing Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Ovulation Inducing Drugs Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Ovulation Inducing Drugs Market

• 9.1. China Ovulation Inducing Drugs Market Overview
• 9.2. China Ovulation Inducing Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Ovulation Inducing Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Ovulation Inducing Drugs Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Ovulation Inducing Drugs Market

• 10.1. India Ovulation Inducing Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Ovulation Inducing Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Ovulation Inducing Drugs Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Ovulation Inducing Drugs Market

• 11.1. Japan Ovulation Inducing Drugs Market Overview
• 11.2. Japan Ovulation Inducing Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Ovulation Inducing Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Ovulation Inducing Drugs Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Ovulation Inducing Drugs Market

• 12.1. Australia Ovulation Inducing Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Ovulation Inducing Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Ovulation Inducing Drugs Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Ovulation Inducing Drugs Market

• 13.1. Indonesia Ovulation Inducing Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Ovulation Inducing Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Ovulation Inducing Drugs Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Ovulation Inducing Drugs Market

• 14.1. South Korea Ovulation Inducing Drugs Market Overview
• 14.2. South Korea Ovulation Inducing Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Ovulation Inducing Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Ovulation Inducing Drugs Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Ovulation Inducing Drugs Market

• 15.1. Western Europe Ovulation Inducing Drugs Market Overview
• 15.2. Western Europe Ovulation Inducing Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Ovulation Inducing Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Ovulation Inducing Drugs Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Ovulation Inducing Drugs Market

• 16.1. UK Ovulation Inducing Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Ovulation Inducing Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Ovulation Inducing Drugs Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Ovulation Inducing Drugs Market

• 17.1. Germany Ovulation Inducing Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Ovulation Inducing Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Ovulation Inducing Drugs Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Ovulation Inducing Drugs Market

• 18.1. France Ovulation Inducing Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Ovulation Inducing Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Ovulation Inducing Drugs Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Ovulation Inducing Drugs Market

• 19.1. Italy Ovulation Inducing Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Ovulation Inducing Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Ovulation Inducing Drugs Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Ovulation Inducing Drugs Market

• 20.1. Spain Ovulation Inducing Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Ovulation Inducing Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Ovulation Inducing Drugs Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Ovulation Inducing Drugs Market

• 21.1. Eastern Europe Ovulation Inducing Drugs Market Overview
• 21.2. Eastern Europe Ovulation Inducing Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Ovulation Inducing Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Ovulation Inducing Drugs Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Ovulation Inducing Drugs Market

• 22.1. Russia Ovulation Inducing Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Ovulation Inducing Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Ovulation Inducing Drugs Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Ovulation Inducing Drugs Market

• 23.1. North America Ovulation Inducing Drugs Market Overview
• 23.2. North America Ovulation Inducing Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Ovulation Inducing Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Ovulation Inducing Drugs Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Ovulation Inducing Drugs Market

• 24.1. USA Ovulation Inducing Drugs Market Overview
• 24.2. USA Ovulation Inducing Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Ovulation Inducing Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Ovulation Inducing Drugs Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Ovulation Inducing Drugs Market

• 25.1. Canada Ovulation Inducing Drugs Market Overview
• 25.2. Canada Ovulation Inducing Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Ovulation Inducing Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Ovulation Inducing Drugs Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Ovulation Inducing Drugs Market

• 26.1. South America Ovulation Inducing Drugs Market Overview
• 26.2. South America Ovulation Inducing Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Ovulation Inducing Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Ovulation Inducing Drugs Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Ovulation Inducing Drugs Market

• 27.1. Brazil Ovulation Inducing Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Ovulation Inducing Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Ovulation Inducing Drugs Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Ovulation Inducing Drugs Market

• 28.1. Middle East Ovulation Inducing Drugs Market Overview
• 28.2. Middle East Ovulation Inducing Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Ovulation Inducing Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Ovulation Inducing Drugs Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Ovulation Inducing Drugs Market

• 29.1. Africa Ovulation Inducing Drugs Market Overview
• 29.2. Africa Ovulation Inducing Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Ovulation Inducing Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Ovulation Inducing Drugs Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Ovulation Inducing Drugs Market Competitive Landscape And Company Profiles

• 30.1. Ovulation Inducing Drugs Market Competitive Landscape
• 30.2. Ovulation Inducing Drugs Market Company Profiles
  • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Johnson And Johnson Pvt Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Merck And Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Abbvie Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Novartis AG Overview, Products and Services, Strategy and Financial Analysis

31. Ovulation Inducing Drugs Market Other Major And Innovative Companies

• 31.1. Bayer AG
• 31.2. Sanofi SA
• 31.3. Abbott Laboratories
• 31.4. Gilead Sciences Inc.
• 31.5. Amgen Inc.
• 31.6. Teva Pharmaceutical Industries Ltd.
• 31.7. Janssen Pharmaceutical Inc.
• 31.8. Mylan N.V
• 31.9. Astellas Pharma Inc.
• 31.10. Sun Pharmaceuticals Industries Ltd.
• 31.11. Aurobindo Pharma Limited
• 31.12. Dr Reddy's Laboratories Ltd.
• 31.13. Intas Pharmaceuticals Limited
• 31.14. Endo International Inc.
• 31.15. Ferring Pharmaceuticals Inc.

32. Global Ovulation Inducing Drugs Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Ovulation Inducing Drugs Market

34. Recent Developments In The Ovulation Inducing Drugs Market

35. Ovulation Inducing Drugs Market High Potential Countries, Segments and Strategies

• 35.1 Ovulation Inducing Drugs Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Ovulation Inducing Drugs Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Ovulation Inducing Drugs Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer